Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
INTSPeer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026 SHELTON, Conn., Jan. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company...
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
INTSSHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and...
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
INTSSHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology...
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
INTS(NASDAQ:INTS) SHELTON, Conn., Sept. 2, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and...
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
INTSSHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and...
Reported Earlier, Intensity Therapeutics Prices Public Offering Of 6.675M Common Shares At $0.30 Per Share For Gross Proceeds Of $2M
INTSIntensity Therapeutics Announces Proposed Public Offering of Common Stock; No Size Or Amount Disclosed
INTSIntensity Therapeutics Says The First Few Patients Receiving INT230-6 Achieved High Levels Of Necrosis After Eight Days In Phase 2 INVINCIBLE-4 Study Prior To Start Of Standard-of-Care
INTSReported Earlier: Intensity Therapeutics To Present Phase 3 INVINCIBLE-3 Trial Poster For INT230-6 In Metastatic Soft Tissue Sarcomas At ASCO 2025 Annual Meeting
INTSIntensity Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate
INTSWhy Intensity Therapeutics (INTS) Stock Is Getting Hammered
INTSIntensity Therapeutics shares are trading lower by 34.9% during Friday's session. The company announced the pricing of a public offering expected to raise approximately $2.35 million.
Intensity Therapeutics, Inc. Announces $2.35M Public Offering At A Combined Purchase Price Per Share And Accompanying Common Warrants Of $0.75
INTSAlliance Global Partners Initiates Coverage On Intensity Therapeutics with Buy Rating, Announces Price Target of $8.5
INTSIntensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients
INTSIntensity Therapeutics Presents INT230-6 Phase 1/2 Data In Sarcoma And An Overview Of Its Ongoing Global Randomized Phase 3 Sarcoma Trial In A Late-Breaking Session At The 2024 Annual Connective Tissue Oncology Society Meeting; Phase 1/2 Data Showed A Med
INTSIntensity Therapeutics And The Swiss Group For Clinical Cancer Research SAKK Dosed First Patient In Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial
INTSHC Wainwright & Co. Initiates Coverage On Intensity Therapeutics with Buy Rating, Announces Price Target of $5
INTSBenchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
INTS